Mithramycin: Difference between revisions
m Protected "Mithramycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
Mithramycin is an anti-neoplastic antibiotic. Its major use is as an IV infusion to reduce very high levels of plasma calcium. It inhibits RNA synthesis in [[osteoclasts]]. Typically use a dose of | Mithramycin is an anti-neoplastic antibiotic. Its major use is as an IV infusion to reduce very high levels of plasma calcium. It inhibits RNA synthesis in [[osteoclasts]]. Typically use a dose of | ||
| Line 7: | Line 7: | ||
Hypercalcaemia recurs in days to several weeks. With repeated use, organotoxicity (kidney, liver, haematopoetic system) can become a problem. | Hypercalcaemia recurs in days to several weeks. With repeated use, organotoxicity (kidney, liver, haematopoetic system) can become a problem. | ||
[[Category: Antibiotics]] | [[Category: Antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 17:28, 9 August 2012
|
WikiDoc Resources for Mithramycin |
|
Articles |
|---|
|
Most recent articles on Mithramycin Most cited articles on Mithramycin |
|
Media |
|
Powerpoint slides on Mithramycin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Mithramycin at Clinical Trials.gov Clinical Trials on Mithramycin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Mithramycin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Mithramycin Discussion groups on Mithramycin Patient Handouts on Mithramycin Directions to Hospitals Treating Mithramycin Risk calculators and risk factors for Mithramycin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Mithramycin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Mithramycin is an anti-neoplastic antibiotic. Its major use is as an IV infusion to reduce very high levels of plasma calcium. It inhibits RNA synthesis in osteoclasts. Typically use a dose of
25 microgram per kilogram IV given over four to six hours. This dose can be repeated in 1 to 2 days if necessary. Ca++ levels start falling after 12 hours, with maximal reduction at 48-72 hours.
Hypercalcaemia recurs in days to several weeks. With repeated use, organotoxicity (kidney, liver, haematopoetic system) can become a problem. Template:WH Template:WikiDoc Sources